MX2009006214A - Moduladores del receptor cb1. - Google Patents
Moduladores del receptor cb1.Info
- Publication number
- MX2009006214A MX2009006214A MX2009006214A MX2009006214A MX2009006214A MX 2009006214 A MX2009006214 A MX 2009006214A MX 2009006214 A MX2009006214 A MX 2009006214A MX 2009006214 A MX2009006214 A MX 2009006214A MX 2009006214 A MX2009006214 A MX 2009006214A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- tetrazolyl
- cooh
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010033307 Overweight Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cycloalkyi Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0625197A GB0625197D0 (en) | 2006-12-18 | 2006-12-18 | Cannabinoid receptor modulators |
| GB0717998A GB0717998D0 (en) | 2007-09-14 | 2007-09-14 | Canabinoid receptor modulators |
| PCT/GB2007/004831 WO2008075012A1 (en) | 2006-12-18 | 2007-12-17 | Cb1 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006214A true MX2009006214A (es) | 2009-06-22 |
Family
ID=39156232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006214A MX2009006214A (es) | 2006-12-18 | 2007-12-17 | Moduladores del receptor cb1. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8148404B2 (enExample) |
| EP (2) | EP2121659B1 (enExample) |
| JP (2) | JP5222855B2 (enExample) |
| CN (1) | CN103145620A (enExample) |
| AU (2) | AU2007336068B2 (enExample) |
| BR (1) | BRPI0720732A2 (enExample) |
| CA (2) | CA2673359A1 (enExample) |
| EA (1) | EA017170B1 (enExample) |
| IL (2) | IL198990A0 (enExample) |
| MX (1) | MX2009006214A (enExample) |
| NZ (1) | NZ578063A (enExample) |
| WO (3) | WO2008075013A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| US7977358B2 (en) | 2007-07-26 | 2011-07-12 | Hoffmann-La Roche Inc. | Pyrazol derivatives |
| NZ585704A (en) | 2007-12-10 | 2012-08-31 | 7Tm Pharma As | Modulators of cannabinoid receptor CB1 for treating obesity |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| WO2013010169A1 (en) | 2011-07-14 | 2013-01-17 | Cook Medical Technologies Llc | A sling to be used in the treatment of obstructive sleep apnea |
| US9710644B2 (en) | 2012-02-01 | 2017-07-18 | Servicenow, Inc. | Techniques for sharing network security event information |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| WO2014189540A1 (en) | 2012-10-16 | 2014-11-27 | Catalano Peter J | Method and apparatus for treating obstructive sleep apnea (osa) |
| CA2919504A1 (en) | 2013-08-01 | 2015-02-05 | Christine BRONIKOWSKI | Tissue adjustment implant |
| CN105392433B (zh) | 2013-08-05 | 2019-02-19 | 库克医学技术有限责任公司 | 具有可释放管状构件的医疗装置及其使用方法 |
| CN104906682A (zh) | 2014-01-24 | 2015-09-16 | 史蒂文·沙勒布瓦 | 铰接气囊导管及其使用方法 |
| US9974563B2 (en) | 2014-05-28 | 2018-05-22 | Cook Medical Technologies Llc | Medical devices having a releasable member and methods of using the same |
| EP3177219B1 (en) | 2014-08-04 | 2018-09-26 | Cook Medical Technologies LLC | Medical devices having a releasable tubular member |
| CN111093572A (zh) | 2017-06-29 | 2020-05-01 | 库克医学技术有限责任公司 | 用于重新定位组织的可植入医疗装置 |
| WO2020041326A1 (en) * | 2018-08-20 | 2020-02-27 | Berkowitz Barry A | Applications of known and novel cannabinoids |
| AU2020417293A1 (en) | 2020-01-03 | 2022-09-01 | Berg Llc | Polycyclic amides as UBE2K modulators for treating cancer |
| WO2026067383A1 (zh) * | 2024-09-27 | 2026-04-02 | 上海轻胜谦远生物科技有限公司 | 咪唑并吡啶衍生物及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| AU780572B2 (en) | 1999-10-18 | 2005-04-07 | University Of Connecticut, The | Pyrazole derivatives as cannabinoid receptor antagonists |
| US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| AU2001234958A1 (en) | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| JP2004500401A (ja) * | 2000-03-23 | 2004-01-08 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Ｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体 |
| GEP20053710B (en) * | 2001-02-28 | 2005-12-26 | Merck & Co Inc | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists |
| AU2002331766A1 (en) | 2001-08-31 | 2003-03-18 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
| FR2831883B1 (fr) * | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| US6825209B2 (en) * | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| JP4419078B2 (ja) * | 2002-12-02 | 2010-02-24 | アステラス製薬株式会社 | ピラゾール誘導体 |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| EP1622876A1 (en) | 2003-05-07 | 2006-02-08 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| FR2856683A1 (fr) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
| BRPI0507786A (pt) | 2004-02-20 | 2007-07-17 | Astrazeneca Ab | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos |
| FR2867685B1 (fr) * | 2004-03-17 | 2008-05-23 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement de la bronchite chronique et de la broncho-pneumopathie chronique obstructive |
| JP2008525404A (ja) | 2004-12-23 | 2008-07-17 | アストラゼネカ アクチボラグ | 治療剤 |
| EP1928859A1 (en) * | 2005-06-17 | 2008-06-11 | Carex SA | Pyrazole derivates as cannabinoid receptor modulators |
| CN101437398A (zh) * | 2006-03-10 | 2009-05-20 | 詹里恩探索公司 | 用于治疗肥胖症的大麻素受体拮抗剂/反向激动剂 |
-
2007
- 2007-12-17 WO PCT/GB2007/004835 patent/WO2008075013A1/en not_active Ceased
- 2007-12-17 CA CA002673359A patent/CA2673359A1/en not_active Abandoned
- 2007-12-17 CN CN2012103916453A patent/CN103145620A/zh active Pending
- 2007-12-17 JP JP2009542200A patent/JP5222855B2/ja not_active Expired - Fee Related
- 2007-12-17 AU AU2007336068A patent/AU2007336068B2/en not_active Ceased
- 2007-12-17 BR BRPI0720732-8A patent/BRPI0720732A2/pt not_active IP Right Cessation
- 2007-12-17 EA EA200900838A patent/EA017170B1/ru not_active IP Right Cessation
- 2007-12-17 EP EP07848579.4A patent/EP2121659B1/en not_active Not-in-force
- 2007-12-17 AU AU2007336061A patent/AU2007336061B2/en not_active Ceased
- 2007-12-17 US US12/518,446 patent/US8148404B2/en not_active Expired - Fee Related
- 2007-12-17 JP JP2009542195A patent/JP5437812B2/ja not_active Expired - Fee Related
- 2007-12-17 US US12/519,432 patent/US8124634B2/en not_active Expired - Fee Related
- 2007-12-17 WO PCT/GB2007/004842 patent/WO2008075019A1/en not_active Ceased
- 2007-12-17 WO PCT/GB2007/004831 patent/WO2008075012A1/en not_active Ceased
- 2007-12-17 CA CA002673177A patent/CA2673177A1/en not_active Abandoned
- 2007-12-17 MX MX2009006214A patent/MX2009006214A/es active IP Right Grant
- 2007-12-17 EP EP07848570.3A patent/EP2121617B1/en not_active Not-in-force
- 2007-12-17 NZ NZ578063A patent/NZ578063A/en not_active IP Right Cessation
-
2009
- 2009-05-27 IL IL198990A patent/IL198990A0/en unknown
- 2009-05-27 IL IL198989A patent/IL198989A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007336061B2 (en) | 2013-06-27 |
| US8124634B2 (en) | 2012-02-28 |
| AU2007336068B2 (en) | 2013-05-02 |
| CA2673359A1 (en) | 2008-06-26 |
| WO2008075012A1 (en) | 2008-06-26 |
| EP2121617B1 (en) | 2014-01-22 |
| JP2010513435A (ja) | 2010-04-30 |
| US8148404B2 (en) | 2012-04-03 |
| EP2121659A1 (en) | 2009-11-25 |
| IL198990A0 (en) | 2010-02-17 |
| EA017170B1 (ru) | 2012-10-30 |
| WO2008075013A1 (en) | 2008-06-26 |
| US20100010061A1 (en) | 2010-01-14 |
| US20100144701A1 (en) | 2010-06-10 |
| AU2007336061A1 (en) | 2008-06-26 |
| AU2007336068A1 (en) | 2008-06-26 |
| JP5222855B2 (ja) | 2013-06-26 |
| WO2008075019A1 (en) | 2008-06-26 |
| JP2010513438A (ja) | 2010-04-30 |
| CA2673177A1 (en) | 2008-06-26 |
| EP2121659B1 (en) | 2013-05-15 |
| JP5437812B2 (ja) | 2014-03-12 |
| BRPI0720732A2 (pt) | 2014-04-08 |
| CN103145620A (zh) | 2013-06-12 |
| NZ578063A (en) | 2011-09-30 |
| EP2121617A1 (en) | 2009-11-25 |
| IL198989A0 (en) | 2010-02-17 |
| EA200900838A1 (ru) | 2010-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200900838A1 (ru) | Модуляторы рецепторов св1 | |
| MX2010006109A (es) | Moduladores de receptores de canabinoides. | |
| HRP20090235B1 (hr) | Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d | |
| MX2010002820A (es) | Analogos de tiazolidindiona para tratamiento de hipertension. | |
| MY157410A (en) | Microbiocidal heterocycles | |
| NO20063866L (no) | 1,3,5-trisubstituerte 4,5-di hydro-1 H-pyrazolderivater med CB1-antagonistisk aktivitet. | |
| MX2009013591A (es) | Proceso para la preparacion de pirazoles. | |
| PH12014500559B1 (en) | Plant disease control composition and its use | |
| PH12014500775A1 (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| WO2008068424A3 (fr) | Derives de 2, 5-dihydro-3h-pyrazolo [4, 3-c] pyridazin-3-one substitues, leur preparation et leur utilisation comme ligands des recepteurs cb1 des cannabinoides | |
| MX2010007019A (es) | Compuestos de bencimidazol. | |
| PH12012502033A1 (en) | Pesticidal composition and its use | |
| MX2009012471A (es) | Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6. | |
| MX2010001566A (es) | Derivado de aminopirazolamida. | |
| MX2009013115A (es) | Derivados de prolinamida como antagonistas de nk3. | |
| ATE464309T1 (de) | Indolizinderivate und deren verwendung als crth2- antagonisten | |
| MX2009008324A (es) | Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6. | |
| MY160905A (en) | Pesticidal composition and its use | |
| MX2010012421A (es) | 5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1. | |
| WO2008136388A1 (ja) | アミド化合物ならびにその植物病害防除用途 | |
| NZ608685A (en) | Novel method of preparing benzoimidazole derivatives | |
| TN2013000546A1 (en) | Microbiocidal heterocycles | |
| WO2009153569A3 (en) | Cb1 receptor modulators | |
| WO2009006267A3 (en) | N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |